> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Biosimilar launch after approval was faster in Japan than in the USA and the EU
- URL: https://www.coios.me/biosimilar-launch-after-approval-was-faster-in-japan-than/
- Published: 2026-11-22T12:50:15.000Z
- Updated: 2026-11-22T13:55:17.000Z
- Description: Japan approved biosimilars later, yet launched them a median 6 months after approval, against 15 (USA) and 17 (EU).
- Author: Daniel Ryan
- Tags: Tomorrow's world, Innovation in treatment, Japan, United States, European Union, #peer-reviewed, #refines, #item, #source-2026-11, #score-50

The study compared biosimilar approval and launch dates in Japan, the USA and the EU. It also measured patient access time, the interval from approval to first commercial launch. Data came from public PMDA, FDA and EMA records, supplemented by company press releases. Median patient access time was 6 months in Japan, 15 months in the USA and 17 months in the EU. Japan still approved biosimilars later, yet its first launches were often as early as or earlier than elsewhere. Launch marks only the earliest point of access, not later uptake in clinical practice.

*Why it is interesting: Approval dates alone can misstate when patients can actually obtain a biosimilar. The authors argue that assessing access also requires looking at post-approval steps such as market entry, pricing and reimbursement.*

Source

[Naunyn-Schmiedeberg's Archives of Pharmacology, 21 November 2026](https://doi.org/10.1007/s00210-026-06048-4?ref=coios.me)

Paper

From regulatory approval to patient access: A comparative analysis of biosimilar market entry timelines in Japan, the USA, and the EU

Authors

Kawasaki M, Saino Y, Nishizawa A, Hariu A, Kuribayashi R

DOI

10.1007/s00210-026-06048-4

Type

Peer-reviewed article

Design

Descriptive comparative analysis of regulatory and launch dates from PMDA, FDA and EMA public records plus company press releases; median approval-to-launch interval compared across three jurisdictions (n of products not stated)

Verdict

Refines prior evidence

Driver

[Innovation in treatment](https://www.coios.me/d-treatment-innovation/)